{
    "nctId": "NCT02523417",
    "briefTitle": "HepaSphere Interventional Therapy Using Digital Subtraction Angiography\uff08DSA\uff09for Breast Cancer",
    "officialTitle": "HepaSphere Interventional Therapy Using Digital Subtraction Angiography\uff08DSA for Breast Cancer: Clinical Trial",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1, PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 15,
    "primaryOutcomeMeasure": "Number of participants with Adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Age:18-80\n2. Karnofsky performance status \\>60\n3. Diagnosis of breast cancer based on histology or the current accepted radiological measures.\n4. Classification tumor,nodes,metastasis-classification(TNM) stage: \u2161,\u2162,\u2163\n5. Will receive interventional therapy\n6. Life expectancy: Greater than 3 months\n7. Patients' routine blood test, liver function and kidney function have no obvious abnormalities\n8. Ability to understand the study protocol and a willingness to sign a written informed consent document\n\nExclusion Criteria:\n\n1. Patients with other primary tumor except breast cancer\n2. History of coagulation disorders or anemia",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}